➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
AstraZeneca
Harvard Business School
Moodys
Colorcon

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

AMERGE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Amerge patents expire, and when can generic versions of Amerge launch?

Amerge is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in AMERGE is naratriptan hydrochloride. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the naratriptan hydrochloride profile page.

Drug patent expirations by year for AMERGE
Drug Prices for AMERGE

See drug prices for AMERGE

Recent Clinical Trials for AMERGE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hartford HealthCarePhase 1/Phase 2
GlaxoSmithKlineN/A
GlaxoSmithKlinePhase 4

See all AMERGE clinical trials

US Patents and Regulatory Information for AMERGE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc AMERGE naratriptan hydrochloride TABLET;ORAL 020763-002 Feb 10, 1998 AB RX Yes No   Start Trial   Start Trial   Start Trial
Glaxosmithkline Llc AMERGE naratriptan hydrochloride TABLET;ORAL 020763-001 Feb 10, 1998 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for AMERGE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc AMERGE naratriptan hydrochloride TABLET;ORAL 020763-002 Feb 10, 1998   Start Trial   Start Trial
Glaxosmithkline Llc AMERGE naratriptan hydrochloride TABLET;ORAL 020763-001 Feb 10, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for AMERGE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0303507 97C0102 Belgium   Start Trial PRODUCT NAME: NARATRIPTAN HYDROCHLORIDUM; REGISTRATION NO/DATE: 725 IS 278 F 3 19970818; FIRST REGISTRATION: SE 13382 19970310
0303507 64/1997 Austria   Start Trial PRODUCT NAME: ''NARATRIPTAN'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATES EINSCHLIESSLICH DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: 1-22059 19970731; FIRST REGISTRATION: SE 13382 19970310
0303507 C970035 Netherlands   Start Trial PRODUCT NAME: NARATRIPTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAA RDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER NARATRIPTAN-HYDROCHLOR IDE; NAT. REGISTRATION NO/DATE: RVG 21444 19970801; FIRST REGISTRATION: SE 13382 19970310
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKinsey
Mallinckrodt
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.